AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$PACS

Murray Jason Hulse sold $2.2M of PACS

Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 51,887 shares of PACS Group, Inc. (PACS) at an average of $43.12 ($42.68–$43.59, $2.24M total) across 5 trades over 2026-09-04 to 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Murray Jason Hulse
Published Sep 9, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PACS
Neutral
medium confidence
Mentioned
$PACS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for PACS.

02

Market read

Insider sales are monitored by traders; this filing adds a new data point for PACS.

03

What to watch

The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.

Relevance 5/10Novelty 7/10Timing: filing today

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$PACSNeutralMedium confidence
Context

CEO Murray Jason Hulse sold 51,887 shares for $2.2M via a 10b5-1 plan, reducing his stake in PACS.

Expected impact

Potential short-term pressure on PACS stock, likely limited to a few percent.

Evidence & confidence

A $2.2M sale by the CEO is material but not large enough to drive a major move; market may view it as routine execution of a pre‑arranged plan.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

Limited to U.S. investors tracking PACS.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • person
    Murray Jason Hulse

    Co‑Founder, CEO & Chairman of PACS

  • company
    PACS Group, Inc.

    Medical device company listed on Nasdaq under ticker PACS

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PACS insider trading history →

Related articles

SEP 2
$PACSHighAI 8/10

Why is PACS stock rallying today?

PACS stock rose 3.3% premarket after announcing two growth initiatives: acquiring 32 Florida nursing facilities and closing 11 more from the Eduro Healthcare deal, expanding its network to 355 buildings. The company's stock has recovered from a 52-week low of $7.50, now trading at $43.52. PACS's low leverage and favorable Medicare reimbursements support its growth strategy.

investing.com2 min
SEP 2
$PACSMed

PACS Group stock rises on Florida expansion, Eduro closings

PACS Group (NYSE:PACS) shares rose 3.3% premarket after announcing plans to acquire 32 Florida skilled nursing facilities, adding 4,049 beds. The deal, expected to close Q4, expands PACS's southern footprint. Additionally, PACS completed closings on 11 more Eduro Healthcare facilities, bringing total Eduro closings to 31 of 34. The company now operates 355 facilities across 7 states. CEO Jason Murray highlighted Florida's growth potential.

investing.com2 min
AUG 4
$PACSHigh

PACS Group, Inc. (PACS): Results of Operations and Financial Condition

PACS Group, Inc. (PACS) filed an SEC Form 8-K — Results of Operations and Financial Condition. PACS Group, Inc. Reports Second Quarter 2026 Results Conference Call and Webcast Scheduled for Tomorrow, August 5, 2026, at 11:30 am ET. SALT LAKE CITY, Utah, August 4, 2026 – PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of

SEC EDGAR 8-K6 min
JUL 3
$PACSMedAI 8/10

Shearwater Group Contract Extension Worth £25m Lifts AIM Shares 17.6%

Shearwater Group said it secured a five-year £25m contract extension with a UK telecoms client, covering packet monitoring and forensic services. £12.5m is to be recognised in 2025-26, but cash is expected after year end; net cash is forecast at £5.6m and pre-tax profit at £1.1m. Shares rose 17.6% to 43.5p. Polar Capital and Supreme also moved on results.

financial-news.co.uk7 min